Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Core Insights - Vaxart, Inc. has initiated a Phase 1 clinical trial for its second-generation oral norovirus vaccine, aiming to demonstrate improved immune responses compared to its first-generation constructs [2][3] - The Phase 1 trial is designed to evaluate safety and immune parameters correlated with protection, with topline data expected as early as mid-2025 [3][4] - If successful, Vaxart plans to conduct a Phase 2 study in the second half of 2025, potentially followed by a Phase 3 trial in 2026 [4] Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform that allows for non-refrigerated storage and eliminates needle-stick injury risks [5] - The company's current development programs include vaccines for norovirus, coronavirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [5] - Vaxart has filed broad patent applications covering its technology for oral vaccination using adenovirus and TLR3 agonists [5]